Improving Patient Lives with Single Cell Precision
HiFiBiO Therapeutics is an emerging multinational company mobilizing the human immune system to combat diseases
Home
Latest News
Jan 6, 2023
HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603
HFB200603 is a novel anti-BTLA Antibody for the treatment of DIS™ Defined Solid Tumors CAMBRIDGE, MA.– January 6, 2023 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for HFB200603. HFB200603 is a novel monoclonal antibody against the … Continued
Jan 5, 2023
HiFiBiO Therapeutics CEO Liang Schweizer Interviewed by Life Science Success Podcast
CAMBRIDGE, MA., – January 5, 2023 – HiFiBiO Therapeutics CEO Liang Schweizer spoke with Don Davis on the Life Science Success Podcast about her professional journey and how HiFiBiO is using its single-cell driven Drug Intelligence Science (DISTM) platform to accelerate the delivery of precision immunotherapies to patients. Link to the podcast here! About HiFiBiO … Continued
Nov 18, 2022
HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200603 in Combination with Tislelizumab in Patients with DIS™ Selected Advanced Solid Tumors
CAMBRIDGE, MA – November 18, 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today a second clinical trial supply agreement with Novartis to evaluate HiFiBiO’s HFB200603, a novel anti-BLTA monoclonal antibody in combination with tislelizumab, Novartis anti-PD-1 immune checkpoint inhibitor, for the treatment of advanced solid tumor indications preselected by HiFiBiO’s proprietary Drug … Continued
Jan 6, 2023
HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603
HFB200603 is a novel anti-BTLA Antibody for the treatment of DIS™ Defined Solid Tumors CAMBRIDGE, MA.– January 6, 2023 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for HFB200603. HFB200603 is a novel monoclonal antibody against the … Continued
Unprecedented Discovery and Development Engine
Uniqueness
Back
Uniqueness
HiFiBiO single-cell focused approach identifies translationally relevant targets, enables rapid drug development, and matches treatments to patients for better clinical outcomes
Innovation
Back
Innovation
Novel Drug Intelligence Science (DIS™) approach combines a cutting-edge single cell platform with data intelligence from public and proprietary patient data to develop novel therapies
Impact
Back
Impact
DIS™ addresses current limitations in drug discovery by linking translationally relevant targets and immunotherapies with the right patient populations to accelerate drug development and increase clinical probability of success
HiFiBiO single-cell focused approach identifies translationally relevant targets, enables rapid drug development, and matches treatments to patients for better clinical outcomes
Novel Drug Intelligence Science (DIS™) approach combines a cutting-edge single cell platform with data intelligence from public and proprietary patient data to develop novel therapies
DIS™ addresses current limitations in drug discovery by linking translationally relevant targets and immunotherapies with the right patient populations to accelerate drug development and increase clinical probability of success